CN105566342A - Novel diterpenoid for treating melanoma and preparation method thereof - Google Patents
Novel diterpenoid for treating melanoma and preparation method thereof Download PDFInfo
- Publication number
- CN105566342A CN105566342A CN201510975941.1A CN201510975941A CN105566342A CN 105566342 A CN105566342 A CN 105566342A CN 201510975941 A CN201510975941 A CN 201510975941A CN 105566342 A CN105566342 A CN 105566342A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- cell
- compound according
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a novel diterpenoid for treating melanoma and a preparation method thereof, and belongs to the technical field of drugs. The diterpenoid reported for the first time is a diterpenoid compound novel in structure, and can be obtained by extracting from dried leaves of whitebackleaf mallotus prior to separation and purification. In-vitro tests prove that the diterpenoid can significantly inhibit growth of melanoma cells, cell number and concentration of the compound (I) decrease in a dependency manner, and the diterpenoid can be used for developing drugs for treating the melanoma.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry leave of Whitebackleaf Mallotus Root, be separated a kind of diterpene-kind compound obtained, containing its pharmaceutical composition and its preparation method and application.
Background technology
Whitebackleaf Mallotus Root is root or the leaf of Euphorbiaceae Euphorbiaceae mallotus plant Whitebackleaf Mallotus Root Mallotusapelta (Lour.) Muell.Arg. [RicinusapeltaLour.], has another name called yeast for brewing rice wine subtree, tunica albuginea leaf etc.Mildly bitter flavor, puckery, property is put down.China is mainly distributed in the ground such as Jiangsu, Anhui, Jiangxi, Fujian, Henan, Guangxi, Hainan, Shaanxi, Yunnan.Whitebackleaf Mallotus Root is extensive at Popular Utilization, and be mainly used as medicine with root and leaf, root has soft liver and invigorates blood circulation, invigorating the spleen for eliminating dampness, and the solid de-effect of convergence, is usually used in chronic hepatitis, hepatosplenomegaly, uterine prolapse, prolapse of the anus, leukorrhea, edema during pregnancy; Leaf energy anti-inflammation hemostasia, mainly external application, is usually used in otitis media, furuncle, wound, traumatic hemorrhage.
This platymiscium contains abundant type of compounds, mainly based on benzo pyran, coumarins, triterpenes and terpenoid.1-benzopyran derivatives is mainly present in the leaf of Whitebackleaf Mallotus Root; Coumarin kind compound is mainly present in leaf, and root and stem also have distribution; Triterpene compound all has distribution in the root of Whitebackleaf Mallotus Root, stem, leaf.Terpenoid, based on diterpenes, is present in leaf.In addition, Whitebackleaf Mallotus Root is also containing alkaloids, flavonoid and volatile component.
Research shows that Whitebackleaf Mallotus Root foliage portion has good hemostasis, antitumor action, root divides and has antiviral and liver-protecting activity preferably, particularly some chemical composition has the activity of strong suppression HIV, reversed transcriptive enzyme or cell dna polymerase, points out it to have and is applied to the potentiality for the treatment of hepatitis B and acquired immune deficiency syndrome (AIDS).In addition, there are some researches show, Whitebackleaf Mallotus Root water decoction has restraining effect to streptococcus aureus, and ethanol extraction can suppress shigella; From root, isolated compound all can suppress streptococcus aureus, Bacillus subtilus, intestinal bacteria and Pseudomonas aeruginosa in varying degrees.Whitebackleaf Mallotus Root decoction and preserved material can make the mortality ratio of oncomelania reach 30% ~ 60%.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry leave of Whitebackleaf Mallotus Root, be separated a kind of diterpene-kind compound obtained, containing its pharmaceutical composition and its preparation method and application.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula:
The preparation method of described compound (I), comprise following operation steps: the dry leave of Whitebackleaf Mallotus Root is pulverized by (a), extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 70% ethanol elution, 8 column volumes, collect 70% elutriant, concentrating under reduced pressure obtains 70% ethanol elution enriched material; C in () step (b), 70% ethanol elution enriched material purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 90:1,60:1,35:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 12 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, in step (a), extract with 75% alcohol heat reflux, united extraction liquid.
Further, described macroporous resin is D101 type macroporous adsorbent resin.
Pharmaceutical composition, the described compound (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the melanomatous medicine of preparation treatment.
The application of described pharmaceutical composition in the melanomatous medicine of preparation treatment.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that compound (I) calculates ECD and experiment ECD figure;
Fig. 3 is BrdU Immunofluorescence test Cell proliferation results.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Main raw, reagent source and instrument type:
Ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, and purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Embodiment 1: compound (I) is separated preparation and structural identification
A the dry leave (10kg) of () Whitebackleaf Mallotus Root is pulverized, (30L × 3 time) are extracted with 75% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (6L), use sherwood oil (6L × 3 time), ethyl acetate (6L × 3 time) and water saturated propyl carbinol (6L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (381g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract D101 macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, use 70% ethanol elution, 8 column volumes again, collect 70% elutriant, concentrating under reduced pressure obtains 70% ethanol elution enriched material (125g); C in () step (b), 70% ethanol elution enriched material purification on normal-phase silica gel is separated, successively with volume ratio be 90:1 (8 column volumes), the methylene chloride-methanol gradient elution of 60:1 (8 column volumes), 35:1 (8 column volumes), 15:1 (10 column volumes) and 1:1 (6 column volumes) obtains 5 components; D component 4 (27g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 20:1 (8 column volumes), the methylene chloride-methanol gradient elution of 15:1 (8 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (15g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 12 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I) (31mg).
Structural identification: HR-ESIMS shows [M+Na]
+for m/z575.2502, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
28h
40o
11, degree of unsaturation is 9.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 500MHz): H-1 (4.68, br, s), H-2 (1.52, m), H-2 (1.91, m), H-3 (1.02, m), H-3 (1.76, td, J=14.5, 3.9), H-6 (5.33, br, s), H-7 (5.04, m), H-8 (1.83, m), H-9 (1.15, td, J=13.2, 4.6), H-11 (1.26, t, J=12.5), H-11 (1.49, m), H-15 (5.95, d, J=2.3), H-16 (6.21, d, J=2.3), H-17 (1.34, s), H-18 (1.01, s), H-19 (1.04, s), H-20 (1.07, s), 1-OAc (2.03, s), 6-OAc (1.93, s), 7-OAc (1.96, s), H-1 ' (3.47, m), H-1 ' (3.78, m), H-2 ' (1.12, m), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 125MHz): 75.0 (CH, 1-C), 22.6 (CH
2, 2-C), 32.2 (CH
2, 3-C), 38.1 (C, 4-C), 79.6 (C, 5-C), 75.3 (CH, 6-C), 74.1 (CH, 7-C), 52.6 (CH, 8-C), 38.3 (CH, 9-C), 42.5 (C, 10-C), 34.0 (CH
2, 11-C), 175.8 (C, 12-C), 57.4 (C, 13-C), 87.7 (C, 14-C), 80.4 (CH, 15-C), 106.1 (CH, 16-C), 23.1 (CH
3, 17-C), 29.5 (CH
3, 18-C), 23.8 (CH
3, 19-C), 16.1 (CH
3, 20-C), 169.1 (C, 1-OAc), 20.7 (CH
3, 1-OAc), 170.9 (C, 6-OAc), 21.5 (CH
3, 6-OAc), 169.0 (C, 7-OAc), 20.8 (CH
3, 7-OAc), 62.4 (CH
2, 1 '-C), 15.4 (CH
3, 2 '-C), carbon atom mark is see Fig. 1.Infrared spectra shows that this compound contains hydroxyl (3470cm
-1) and carbonyl (1757,1725cm
-1) group.
1hNMR spectrum demonstrates four containing oxygen methine signals δ H4.68 (br, s, H-1), 5.33 (br, s, H-6), 5.04 (m, H-7), 5.95 (d, J=2.3Hz, H-15) and 6.21 (d, J=2.3Hz, H-16); Two methyne δ H1.83 (m, H-8) and 1.15 (td, J=13.2,4.6Hz, H-9); Three acetyl-o-methyls; Five methyl δ H1.34 (H-17), 1.01 (H-18), 1.04 (H-19), 1.07 (H-20), 1.12 (H-2 ').
13cNMR spectrum shows 28 signals, containing eight methyl, and four methylene radical (containing oxygen), seven methynes (five containing oxygen carbon) and nine quaternary carbons (four carbonyl carbon, two containing oxygen quaternary carbon).Above-mentioned data show, this compound is the tricyclic diterpene compounds replaced containing three acetoxyl groups.H-1 (δ H4.68, br, s), H-6 (δ H5.33, br, s) with H-7 (δ H5.04, m) dependency of its corresponding acetoxyl group (δ C169.1,170.9,169.0), show C-1 (δ C75.0), C-6 (δ C75.3) and C-7 (δ C74.1) position are connected with an acetoxyl group respectively.In HMBC spectrum, the dependency of Me-17 and C-8, C-13 and C-14 shows that C-17 position is methyl.In HMBC spectrum, the dependency of H-15 and C-14 shows that this compound contains trimethylene oxide part.In ROESY spectrum, the dependency of H-1 and Me-20, Me-20 and H-8, H-8 and H-6 and H-6 and Me-19 shows H-1, and H-6, H-8, Me-19 and Me-20 are β type configuration, and the intersection peak of H-9 and H-7 shows the α configuration of these protons.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and ROESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
People A375 melanoma cell strain is given by Third Military Medical University.Compound (I) is made by oneself, and preparation method is shown in that embodiment 1, HPLC normalization method purity is greater than 98%.DMEM substratum, 0.25% pancreatin purchased from American Gibco company.MTT (3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide bromine salt; Methyl thiazoly tetrazolium assay), DMSO (dimethyl sulfoxide (DMSO)), BrdU purchased from American Sigma company.Mouse-anti BrdU polyclonal antibody purchased from American ABcam company.Goat against murine two anti-purchased from American Cellsignaling company.AnnexinV-FITC/PI cell apoptosis detection kit purchased from American Promega company.
Constant temperature CO
2incubator, general refrigerator ,-80 degree refrigerators are U.S. Forma Products.Bechtop (Chinese Suzhou cleaning project company).Inverted microscope, inverted fluorescence microscope (olympus company).Electro-heating standing-temperature cultivator (Chinese Shanghai leap medical apparatus and instruments factory).Automatic microplate reader (Japanese Wako company).UV detector (Beckman company of the U.S.).J6-HC supercentrifuge (Beckman company of the U.S.).Low-temperature trace whizzer (German Eppendorf company).Vibration shaking table (Forma company of the U.S.).
Two, test method
1, cell cultures
1.1 cell recovery
Frozen A375 melanoma cell in liquid nitrogen container taken out, put into rapidly the warm water of 37 DEG C, shake makes it melt as early as possible (about lmin) gently.Then sucking-off cell suspension, joins in the centrifuge tube being added with 2mL substratum, blows and beats mixing gently, 800r/min, and centrifugal 5min discards upper strata substratum.After making cell suspension with the DMEM substratum 8mL of the mould G/ Streptomycin sulphate containing 10%FBS and 1%, be seeded in 10cm culture plate.Then 5%CO is placed in
2, cultivate in 37 DEG C of constant incubators.
1.2 passage
Basis of microscopic observation cytogamy degree can go down to posterity when reaching 80%-90%.First use 2mLPBS washed cell 2 times, then add the pancreatin lmL of 0.25%.Horizontal wave and culture dish gently, makes Digestive system can cover the surface of cell, is then placed in 37 DEG C of incubators and digests about lmin.See that cell rounding bounces back under being placed in microscope, then add rapidly the substratum termination digestion that 1mL contains FBS.Blow and beat to cell dispersal even gently, then go down to posterity according to 1:2 or 1:3 according to cell density, be re-seeded in new culture plate, be placed in 5%CO
2, cultivate in 37 DEG C of constant incubators.
1.3 cell cryopreservation
Get the cell that 1 dish is in logarithmic phase, trysinization is also collected in centrifuge tube, and the centrifugal 5min of 1000r/min, abandons supernatant.Then add lmL frozen storing liquid, dispel cell gently and make cell suspension, cell suspension is joined in the cryopreservation tube of 1.5mL.In the title of cryopreservation tube subscript clear-cells, shelf time, the name of preserver.First cryopreservation tube is put into 4 DEG C of refrigerators, place about 30min.Then be placed in-20 DEG C of refrigerators, place about 2h.Then be put in-80 DEG C of Ultralow Temperature Freezers to place and spend the night.Frozen cell was placed in the medium-term and long-term preservation of liquid nitrogen container in second day.
2, cell counting draws cell growth curve
(1) take the logarithm A375 melanoma cell in vegetative period, counting, adjustment cell density is 2 × 10
4/ mL.
(2) by cell suspension inoculation in 12 orifice plates, 1.5mL/ hole.
(3) after 12h, treat cell attachment, change 1mL plasma-free DMEM medium, and use 5 μm of ol/L compounds (I) and DMSO (for the compound (I) of DMSO dilution respectively, control DMSO concentration is below 1/1000, guarantee cell harmless) process, often organize cell and establish 3 parallel holes, be placed in 5%C02,37 DEG C of constant incubators are cultivated.
(4) stop cultivating respectively at 0h, 24h, 48h, 72h, 96h, collect each group of cell, add 0.25% tryptic digestion, centrifugal, resuspended.
(5) cell counting: draw cell suspension 10 μ L, add isopyknic phenol blue area and divide viable cell, draw 10 μ L mixed solutions and add in cell counting count board groove gently, ensure tight and bubble.Under inverted microscope, the cell count in counting periphery four block plaid, substitutes into formula: archeocyte suspension concentration (cell count/mL)=(cell count/4 of 4 block plaid) × 10
4× extension rate.
(6) calculate number of viable cells, draw cell growth curve.
3, mtt assay detects cell proliferation
(1) the A375 cell of taking the logarithm vegetative period, digestion, centrifugal, resuspended, counting, in adjustment cell suspension, the density of cell is 2 × 10
4/ mL.
(2) by each group of cell suspension inoculation in 96 well culture plates, the 200 every holes of μ L, often organize cell 3 parallel holes, establish blank control wells (only adding substratum) simultaneously.
(3) 12h is after cell attachment, changes 200 μ L plasma-free DMEM medium, and uses 5 μm of ol/L compounds (I) and DMSO process respectively.
(4) stopped cultivating respectively at 0,1,2,3,4 day.
(5) add Methyl thiazoly tetrazolium assay (MTT) the 20 μ L that concentration is 5mg/mL to every hole and continue culturing cell 4h.
(6) inhale the substratum abandoned in each aperture, add 200 μ LDMSO, microoscillator is vibrated 10min, and crystallisate is fully dissolved.
(7) return to zero with blank control wells, automatic microplate reader is adopted to measure the absorption photometric value (OD value) at 570nm place, each hole, ability of cell proliferation is represented with the OD value of correspondence, the each group of mean value getting 3 parallel holes, take time as transverse axis, with each absorbance for the longitudinal axis draws cell growth curve.
4, BrdU Immunofluorescence test cell proliferation
(1) creep plate is prepared: creep plate is put into 75% alcohol and soak 24h and disinfect.
(2) aseptic creep plate is placed in 24 well culture plates, the A375 melanoma cell in vegetative period of taking the logarithm, digestion, centrifugal, make cell suspension, 2 × 10
4cell/ hole, is inoculated in and is placed with in the hole of creep plate.
(3) 12h is after cell attachment, changes 1mL plasma-free DMEM medium, and uses 5 μm of ol/L compounds (I) and DMSO process respectively.
(4) after 72h, add 10 μ lBrdU (1mg/mL) in the medium, cultivate 1h for 37 DEG C.
(5) take out 24 orifice plates, wash 5min × 2 time with cold PBS, 4% paraformaldehyde fixed cell, room temperature 30min.
(6) PBS washes 5min × 3 time.
(7) 2mol/LHCl process, after room temperature 10min, 37 DEG C of 20min.
(8) the penetrating process in cell 1%Triton ×-100, washes 5min × 3 time.
(9) 10% lowlenthal serums are closed, room temperature, lh.
(10) BrdU monoclonal antibody (1:300 dilution) is added, 37 DEG C of 1.5h.
(11) l × PBST shakes and washes 5min × 3 time.
(12) add BrdU bis-anti-(1:300), after room temperature lucifuge 1h, l × PBST washes 3 times.
(13) DAPI staining fluid transfect cell core 15min.
(14) PBS washes 5min × 3 time.
(15) 1 anti-fluorescent quenching mounting liquid is added, neutral gum mounting, fluorescence microscopy Microscopic observation, photograph.
5, statistical study
Application SPSS17.0 statistical analysis software, adopt two independent samples t test and one-way analysis of variance to carry out data analysis, data X ± S represents, P<0.05 is for there being statistical significance.
Three, result and conclusion
Cellular form is observed and counting display, and with DMSO control group ratio, after compound (I) process A375 cell 24h, 48h, 72h, viable count significantly reduces and reaches 44.5%.The results are shown in Table 1 (with control group ratio
*p<0.05,
*p<0.01, lower same).
MTT result shows, and compound (I) can significantly suppress A375 cell proliferation, and OD value is that the decline of concentration (5 μm of ol/L, 10 μm of ol/L, 20 μm of ol/L) dependency reaches 27.3%, and difference has statistical significance.The results are shown in Table 2.
Compound (I) energy check melanin tumor cell proliferation is confirmed further by BrdU immunofluorescence dyeing, 5 μm of ol/L compound (I) process A375 cells are after 3 days, compared with contrast (26.07 ± 2.59%), experimental group BrdU positive cell percentage (7.55 ± 2.76%) significantly reduces (P=0.000).The results are shown in Figure 3 (* * P<0.01).
This experiment have detected the impact that compound (I) is bred melanoma cell, cell counting and MTT analytical results all prove that compound (I) can remarkable check melanin tumor cell growth, and cell count and compound (I) concentration are that dependency declines.After BrdU immunofluorescence dyeing also shows compound (I) process, BrdU positive cell percentage is significantly lower than control group, illustrates that compound (I) can suppress A375 melanoma cell to be bred.Compound (I) may be melanomatous efficient targeting medicine.
Table 1 compound (I) dose-dependent inhibition A375 cell proliferation (cell counting, unit: × l0
4/ mL)
| Group | 0h | 24h | 48h | 72h | 96h |
| DMSO | 2.87±0.23 | 4.72±0.30 | 7.36±0.13 | 7.56±0.39 | 8.04±0.27 |
| Compound (I)-5 μm of ol/L | 2.87±0.23 | 3.87±0.36* | 3.48±0.32** | 3.40±0.34** | 2.54±0.41** |
| Compound (I)-10 μm of ol/L | 2.87±0.23 | 2.36±0.28** | 2.95±0.37** | 1.56±0.36** | 0.89±0.26** |
Table 2 compound (I) dose-dependent inhibition A375 cell proliferation (mtt assay, OD570)
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:7 in itself and excipient weight.
Embodiment 4
The preparation of oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula:
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry leave of Whitebackleaf Mallotus Root is pulverized by (a), extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; B in () step (a), the removal of impurities of thing macroporous resin got by propyl carbinol, first use 10% ethanol elution, 6 column volumes, then use 70% ethanol elution, 8 column volumes, collect 70% elutriant, concentrating under reduced pressure obtains 70% ethanol elution enriched material; C in () step (b), 70% ethanol elution enriched material purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 90:1,60:1,35:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 12 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: in step (a), extracts, united extraction liquid with 75% alcohol heat reflux.
4. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is D101 type macroporous adsorbent resin.
5. a pharmaceutical composition, is characterized in that: the compound according to claim 1 (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the melanomatous medicine of preparation treatment.
7. the application of pharmaceutical composition according to claim 5 in the melanomatous medicine of preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510975941.1A CN105566342A (en) | 2015-12-22 | 2015-12-22 | Novel diterpenoid for treating melanoma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510975941.1A CN105566342A (en) | 2015-12-22 | 2015-12-22 | Novel diterpenoid for treating melanoma and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105566342A true CN105566342A (en) | 2016-05-11 |
Family
ID=55877031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510975941.1A Pending CN105566342A (en) | 2015-12-22 | 2015-12-22 | Novel diterpenoid for treating melanoma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105566342A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105461531A (en) * | 2016-01-12 | 2016-04-06 | 郑平珍 | Novel sesquiterpene compound and preparation method and medical application thereof |
| CN105566300A (en) * | 2016-01-21 | 2016-05-11 | 李宇花 | Novel alkaloid compound and preparation method and medical application thereof |
| CN107434764A (en) * | 2016-05-29 | 2017-12-05 | 戴明虎 | It is a kind of to be used to treat new triterpene compound of melanoma and preparation method thereof and medical usage |
Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316096A (en) * | 2012-03-23 | 2013-09-25 | 上海中医药大学 | General flavone extract of seeds of nigella damascena l., nigella sativa l. or nigella glandulifera freyn et sint., and preparation method and use thereof |
| CN103768042A (en) * | 2012-10-19 | 2014-05-07 | 上海中医药大学 | Application of licochalcone A to prepare anticancer medicines or health-care products |
| CN105061456A (en) * | 2015-09-13 | 2015-11-18 | 周午贤 | Novel kaurene diterpenoid compound and preparation method and pharmaceutical application thereof |
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105055382A (en) * | 2015-09-13 | 2015-11-18 | 赵东顺 | Application of pedinophyllol C in preparation of medicine for treating melanoma |
| CN105078967A (en) * | 2015-09-05 | 2015-11-25 | 林天样 | Application of Phaeocaulisin A in preparation of drug for treating melanoma |
| CN105198845A (en) * | 2015-10-09 | 2015-12-30 | 吴正锋 | Novel diterpene compound for treating glioma |
| CN105294619A (en) * | 2015-10-21 | 2016-02-03 | 淄博夸克医药技术有限公司 | Novel diterpene compound and preparation method and medical application thereof |
| CN105330674A (en) * | 2015-12-07 | 2016-02-17 | 西宁意格知识产权咨询服务有限公司 | New diterpenoid compound and preparation method and medical application thereof |
| CN105330636A (en) * | 2015-12-07 | 2016-02-17 | 西宁意格知识产权咨询服务有限公司 | New flavonoid compound and preparation method and medical application thereof |
| CN105439989A (en) * | 2015-12-31 | 2016-03-30 | 胡文杰 | Novel diterpenoid compounds as well as preparation method and medicine application thereof |
| CN105481881A (en) * | 2015-12-30 | 2016-04-13 | 吴金凤 | Novel diterpene alkaloid compound and preparation method and medical application thereof |
| CN105503778A (en) * | 2015-12-30 | 2016-04-20 | 吴金凤 | Grayanotoxin compound and preparation method and medical application thereof |
| CN105503999A (en) * | 2015-12-31 | 2016-04-20 | 吴金凤 | Limonin compounds for treating melanoma and preparation method thereof |
| CN105503795A (en) * | 2015-12-31 | 2016-04-20 | 吴金凤 | Cyclofarnesane type sesquiterpene compound as well as preparation method and medical application thereof |
| CN105524075A (en) * | 2015-12-29 | 2016-04-27 | 吴金凤 | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound |
| CN105566300A (en) * | 2016-01-21 | 2016-05-11 | 李宇花 | Novel alkaloid compound and preparation method and medical application thereof |
| CN105663118A (en) * | 2016-02-26 | 2016-06-15 | 温州统益生物医药科技有限公司 | Application of flavonoids compound to preparation of neuroprotection medicament |
-
2015
- 2015-12-22 CN CN201510975941.1A patent/CN105566342A/en active Pending
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316096A (en) * | 2012-03-23 | 2013-09-25 | 上海中医药大学 | General flavone extract of seeds of nigella damascena l., nigella sativa l. or nigella glandulifera freyn et sint., and preparation method and use thereof |
| CN103768042A (en) * | 2012-10-19 | 2014-05-07 | 上海中医药大学 | Application of licochalcone A to prepare anticancer medicines or health-care products |
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105078967A (en) * | 2015-09-05 | 2015-11-25 | 林天样 | Application of Phaeocaulisin A in preparation of drug for treating melanoma |
| CN105061456A (en) * | 2015-09-13 | 2015-11-18 | 周午贤 | Novel kaurene diterpenoid compound and preparation method and pharmaceutical application thereof |
| CN105055382A (en) * | 2015-09-13 | 2015-11-18 | 赵东顺 | Application of pedinophyllol C in preparation of medicine for treating melanoma |
| CN105198845A (en) * | 2015-10-09 | 2015-12-30 | 吴正锋 | Novel diterpene compound for treating glioma |
| CN105294619A (en) * | 2015-10-21 | 2016-02-03 | 淄博夸克医药技术有限公司 | Novel diterpene compound and preparation method and medical application thereof |
| CN105330674A (en) * | 2015-12-07 | 2016-02-17 | 西宁意格知识产权咨询服务有限公司 | New diterpenoid compound and preparation method and medical application thereof |
| CN105330636A (en) * | 2015-12-07 | 2016-02-17 | 西宁意格知识产权咨询服务有限公司 | New flavonoid compound and preparation method and medical application thereof |
| CN105524075A (en) * | 2015-12-29 | 2016-04-27 | 吴金凤 | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound |
| CN105481881A (en) * | 2015-12-30 | 2016-04-13 | 吴金凤 | Novel diterpene alkaloid compound and preparation method and medical application thereof |
| CN105503778A (en) * | 2015-12-30 | 2016-04-20 | 吴金凤 | Grayanotoxin compound and preparation method and medical application thereof |
| CN105439989A (en) * | 2015-12-31 | 2016-03-30 | 胡文杰 | Novel diterpenoid compounds as well as preparation method and medicine application thereof |
| CN105503999A (en) * | 2015-12-31 | 2016-04-20 | 吴金凤 | Limonin compounds for treating melanoma and preparation method thereof |
| CN105503795A (en) * | 2015-12-31 | 2016-04-20 | 吴金凤 | Cyclofarnesane type sesquiterpene compound as well as preparation method and medical application thereof |
| CN105566300A (en) * | 2016-01-21 | 2016-05-11 | 李宇花 | Novel alkaloid compound and preparation method and medical application thereof |
| CN105663118A (en) * | 2016-02-26 | 2016-06-15 | 温州统益生物医药科技有限公司 | Application of flavonoids compound to preparation of neuroprotection medicament |
Non-Patent Citations (1)
| Title |
|---|
| YONG ZHENG等，: ""Caesalminaxins A−L, Cassane Diterpenoids from the Seeds of Caesalpinia minax"", 《J. NAT. PROD.》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061548A (en) * | 2015-08-19 | 2015-11-18 | 庄立 | Novel withanolides compound and preparation method and medical application thereof |
| CN105461531A (en) * | 2016-01-12 | 2016-04-06 | 郑平珍 | Novel sesquiterpene compound and preparation method and medical application thereof |
| CN105566300A (en) * | 2016-01-21 | 2016-05-11 | 李宇花 | Novel alkaloid compound and preparation method and medical application thereof |
| CN107434764A (en) * | 2016-05-29 | 2017-12-05 | 戴明虎 | It is a kind of to be used to treat new triterpene compound of melanoma and preparation method thereof and medical usage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105061456A (en) | Novel kaurene diterpenoid compound and preparation method and pharmaceutical application thereof | |
| CN105330674A (en) | New diterpenoid compound and preparation method and medical application thereof | |
| CN105481881A (en) | Novel diterpene alkaloid compound and preparation method and medical application thereof | |
| CN105061548A (en) | Novel withanolides compound and preparation method and medical application thereof | |
| CN104961791B (en) | A kind of new triterpenoid, preparation method and purposes in Radix potentillae anserinae | |
| CN105566342A (en) | Novel diterpenoid for treating melanoma and preparation method thereof | |
| CN105503999A (en) | Limonin compounds for treating melanoma and preparation method thereof | |
| CN105152895A (en) | New meroterpenoid as well as preparation method and medical application thereof | |
| CN105198845A (en) | Novel diterpene compound for treating glioma | |
| CN105330673A (en) | Novel limonin compound and preparation method and medical application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105294619A (en) | Novel diterpene compound and preparation method and medical application thereof | |
| CN105524075A (en) | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN105384750A (en) | Kauran diterpene compound for curing renal cancer | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105503778A (en) | Grayanotoxin compound and preparation method and medical application thereof | |
| CN105524063A (en) | Novel terpene indole alkaloid compound, and preparation method and medical application thereof | |
| CN105418545A (en) | Novel isocoumarin compound and preparation method and medical application thereof | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer | |
| CN106397369A (en) | Novel labdane-type diterpenoid compound, preparation method and application thereof, pharmaceutical composition and application of pharmaceutical composition | |
| CN105254497A (en) | Novel diterpenoid compound and preparation method and medical application thereof | |
| CN106074499A (en) | The application in medicine of a kind of Crow alkane type diterpene-kind compound | |
| CN105566438A (en) | Limonin compound for treating neuroglioma, and preparation method thereof | |
| CN105439989A (en) | Novel diterpenoid compounds as well as preparation method and medicine application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160511 |
|
| WD01 | Invention patent application deemed withdrawn after publication |